Pick a compound and the date of your first injection to get a dated, week-by-week escalation table. Doses follow the approved label where one exists (tirzepatide, semaglutide) and the published Phase 2 trial protocol where one does not (retatrutide).
Reviewed for accuracy · Last reviewed July 8, 2026| Phase | Weekly dose | Starting |
|---|---|---|
| Weeks 1–4 | 2.5 mg | - |
| Weeks 5–8 | 5 mg | - |
| Weeks 9–12 | 7.5 mg | - |
| Weeks 13–16 | 10 mg | - |
| Weeks 17–20 | 12.5 mg | - |
| Week 21+ | 15 mg (maximum) | - |
Follows the weight-management label (Zepbound): start at 2.5 mg once weekly and increase in 2.5 mg steps no sooner than every 4 weeks. The steps past 5 mg are optional; the label's maintenance doses are 5 mg, 10 mg, or 15 mg, and many people hold at a lower step.
All three compounds share the same pattern: gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are most common while the dose is climbing, and settle for most people once it stabilizes. The 4-week hold at each step gives the gut time to adjust, which is why the labels say increases should come no sooner than every 4 weeks.
The planner shows the fastest schedule the label or trial protocol allows. Holding a step longer, or stopping at a lower maintenance dose, is common and consistent with the labels. Once you know your weekly dose, the reconstitution calculator converts it to a syringe draw for your vial, and the vial duration calculator shows how long each vial will last at that dose.
This tool is an independent educational reference and is not medical advice. Titration decisions belong with a prescribing clinician; talk to a doctor before starting or adjusting any compound.